Smoking Cessation Pipeline Insight

DelveInsight’s, “Smoking Cessation- Pipeline Insight, 2023” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Smoking Cessation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Smoking Cessation: Understanding

Smoking Cessation: Overview

Tobacco use, primarily cigarette smoking, is the leading cause of preventable disease and death in the United States. It is well established that smoking increases the risk of different forms of cancer, including lung, liver, and colorectal. Eighty-five percent of lung cancers occur in smokers. Also, smoking increases the risk of respiratory diseases (such as chronic obstructive pulmonary disease) and cardiovascular disease. During pregnancy, smoking increases the rate of complications, including miscarriage, stillbirth, preterm birth, fetal growth restriction, and congenital anomalies. Neonatal and pediatric complications of exposure to cigarette smoking include sudden infant death syndrome and abnormal lung function in children, such as asthma. Assisting patients with smoking cessation is one of the most important primary care tasks, and the benefits of assessing patients’ smoking behavior are well established. Smoking cessation is the most important of the modifiable risk factors for cardiovascular disease. The products of tobacco smoke contribute directly and distinctly to the development of atherosclerosis and its adverse consequences. Smoking cessation is likely to be more effective if delivered as an integral component of a multifaceted country or population-level tobacco control program. While focused on reducing uptake of smoking and reducing consumption and smoking prevalence, many tobacco control program strategies can prompt smokers to make a quit attempt. Smoking cessation can have positive health effects, including an improvement in all-cause mortality. Although duration of cessation counseling from a healthcare provider correlates with likelihood of abstinence, providers would be mistaken to believe that extensive time investments are necessary to have an impact: even individualized interventions as short as 1 minute have been shown to increase quitting success. Pharmacotherapy interventions approved by the FDA for the treatment of tobacco dependence in adults include bupropion SR, varenicline, and NRT (nicotine replacement therapy). Behavioral interventions found to be effective in aiding adults in smoking cessation include in-person counseling, telephone counseling, and self-help materials. These interventions may increase rates of smoking cessation from a baseline of 5% to 11% in control groups to 7% to 13% in intervention groups. More intensive behavioral therapies like group or individual counseling sessions improve the odds of cessation when compared to minimal advice.

"Smoking Cessation- Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Smoking Cessation pipeline landscape is provided which includes the disease overview and Smoking Cessation treatment guidelines. The assessment part of the report embraces, in depth Smoking Cessation commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Smoking Cessation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Smoking Cessation R&D. The therapies under development are focused on novel approaches to treat/improve Smoking Cessation.

Smoking Cessation Emerging Drugs Chapters

This segment of the Smoking Cessation report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Smoking Cessation Emerging Drugs

EMB-001: Embera NeuroTherapeutics, Inc.

EMB-001 is a patented combination product comprising two FDA-approved medications, the cortisol synthesis inhibitor metyrapone and the benzodiazepine oxazepam. The innovation is based on insights into the physiologic responses to stress in addiction. EMB-001 is thought to act by mechanisms distinct from those of existing addiction treatments and is hypothesized to reduce the increased activity in the stress response system induced by drugs, cues and stressors that contribute to relapse in addiction. EMB-001 may potentially reduce the cravings and loss of control that drive relapse in addiction, by uniquely targeting multiple pathways, thereby possibly maximizing potential efficacy. Currently, the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Smoking Cessation.

SBP 9330: Camino Pharma

SBP–9330 is a novel selective positive allosteric modulator of the metabotropic glutamate receptor 2 (mGlu2).It is designed to reduce levels of glutamate, a neurotransmitter linked to addiction and relapse behavior. Preclinical studies of SBP-9330, supported by a previous NIDA grant awarded to the same three institutions, demonstrated that the drug candidate reduces nicotine self-administration in animal models and is safe and well tolerated in preclinical safety and toxicology studies.

Further product details are provided in the report……..

Smoking Cessation: Therapeutic Assessment

This segment of the report provides insights about the different Smoking Cessation drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Smoking Cessation

There are approx. 13+ key companies which are developing the therapies for Smoking Cessation. The companies which have their Smoking Cessation drug candidates in the most advanced stage, i.e. Phase II/III include, Embera NeuroTherapeutics, Inc.

Phases

DelveInsight’s report covers around 13+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Smoking Cessation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Smoking Cessation: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Smoking Cessation therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Smoking Cessation drugs.

Smoking Cessation Report Insights

• Smoking Cessation Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Smoking Cessation Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Smoking Cessation drugs?
• How many Smoking Cessation drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Smoking Cessation?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Smoking Cessation therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Smoking Cessation and their status?
• What are the key designations that have been granted to the emerging drugs?